Zainab Alnafoosi, MD

Zainab Alnafoosi, MD

Assistant Professor of Clinical Internal Medicine
Internal Medicine

    About me

    Gender

    Female

    Education & training

    Positions
    Infectious Diseases Physician
    Board Certifications
    American Board of Internal Medicine - Internal Medicine
    American Board of Internal Medicine - Infectious diseases
    Medical School
    Dubai Medical College, Dubai, United Arab Emirates
    Residency
    Interfaith Medical Center, Brooklynn NY
    Fellowship
    State University of New York - Downstate Health Sciences University, Brooklyn, NY

    Awards

    • Was awarded the Standard of Excellence upon graduation and the Third Rank of the 2011 Class by Sheikh Mohamed Bin Rashid Al-Maktoom, Prime Minister of United Arab Emirates, 2011.
    • Was awarded the Certificate of standard of excellence for the Clinical Science Examination of the International Foundations of Medicine (IFOM) from the National Board of Medical Examiners (NBME), 2010.

    Clinical trials

    Trial
    Infectious Diseases

    A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium aviu

    Active recruiting

    The purpose of this clinical trial is to assess the effectiveness of Epetraborole, taken once daily, in patient populations with treatment-refractory MAC lung disease.

    Eligible patients include those who currently have a positive MAC sputum culture despite receiving a combination regimen of at least 2 antimycobacterial agents administered for at least 6 months.

    Contact: Katherine Martz 217-545-4342
    Trial
    Infectious Diseases

    A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium aviu

    Active recruiting

    The purpose of this clinical trial is to assess the effectiveness of Epetraborole, taken once daily, in patient populations with treatment-refractory MAC lung disease.

    Eligible patients include those who currently have a positive MAC sputum culture despite receiving a combination regimen of at least 2 antimycobacterial agents administered for at least 6 months.

    Contact: Katherine Martz 217-545-4342